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Summary. We introduce a non-myopic, covariate-adjusted response adaptive (CARA) allocation design for multi-armed
clinical trials. The allocation scheme is a computationally tractable procedure based on the Gittins index solution to the
classic multi-armed bandit problem and extends the procedure recently proposed in Villar et al. (2015). Our proposed CARA
randomization procedure is defined by reformulating the bandit problem with covariates into a classic bandit problem in
which there are multiple combination arms, considering every arm per each covariate category as a distinct treatment arm.
We then apply a heuristically modified Gittins index rule to solve the problem and define allocation probabilities from the
resulting solution. We report the efficiency, balance, and ethical performance of our approach compared to existing CARA
methods using a recently published clinical trial as motivation. The net savings in terms of expected number of treatment
failures is considerably larger and probably enough to make this design attractive for certain studies where known covariates
are expected to be important, stratification is not desired, treatment failures have a high ethical cost, and the disease under
study is rare. In a two-armed context, this patient benefit advantage comes at the expense of increased variability in the
allocation proportions and a reduction in statistical power. However, in a multi-armed context, simple modifications of the
proposed CARA rule can be incorporated so that an ethical advantage can be offered without sacrificing power in comparison
with balanced designs.
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1. Introduction
The Gittins index rule (Gittins and Jones, 1979) was devel-
oped as an optimal solution to the classic multi-armed bandit
problem. In the context of a clinical trial to test the effec-
tiveness of several treatments with an infinite number of
patients, it also provides a deterministic patient allocation
rule that aims to optimize patient benefit on average. In order
to do so, the rule must dynamically address the ethical con-
flict between learning (efficiency/power) and earning (patient
benefit/ethics) after every patient is treated, its outcome
observed and considering the potential outcomes of the future
patients, given the observed history.
The multi-armed bandit problem and the Gittins index
are based on a set of assumptions which may be restrictive
when considered from a practical point of view (Villar et al.,
2015). Particularly important assumptions include the infinite
size of the trial, the observability of each patient’s outcome
before treating the next patient, and the lack of randomiza-
tion of the resulting patient allocation rule. Any extensions
of the original model that result from relaxing some (or all)
of these assumptions would, in general, require either find-
ing an appropriate extension of the Gittins index rule for the
relaxed model (e.g., an index for the finite horizon problem
investigated by Villar et al. (2015)), or otherwise relying on
a computational solution using dynamic programming (e.g.,
as in Cheng and Berry (2007) or Williamson et al. (2017)).
The latter approach requires the problem to be of a tractable
size. An alternative approach was proposed in Villar et al.
(2015) where the Gittins index rule was used to define a
non-myopic response-adaptive randomized procedure for the
design of finite-sized trials—namely, the block randomization
procedure referred to as the forward looking Gittins index
(FLGI).
Incorporating covariates into the multi-armed bandit model
is one such extension. There are at least two reasons why this
would be relevant. First, including covariate information into
the model would imply relaxing the assumption that observa-
tions of a given treatment are exchangeable (i.e., that subjects
receiving the same treatment arm have the same probabil-
ity of success). This would, in turn, allow for the inclusion
of treatment–covariate interactions and the modified ban-
dit model with covariates would maximize patient benefit by
assigning more patients to a superior treatment, given their
covariate profile. Second, methods that promote balance on
important known covariates have become a general standard
among practicing clinical trialists. However, there are many
relevant instances in which balance does not lead to efficiency
or ethically attractive designs, as shown in Rosenberger and
Sverdlov (2008). A bandit model with covariates would illus-
trate this conflict, as balance on covariates would never be
achieved by its optimal solution rule if treatments are per-
ceived differently among covariate groups.
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In this article, we address the issue of introducing covariates
into the classic multi-armed bandit model. We first present a
deterministic implementation of the Gittins index that makes
use of covariate information, and then use it to define a
covariate-adjusted response-adaptive (CARA) randomization
procedure that is non-myopic and applied to blocks of patients
rather than individuals, as suggested by Rosenberger and
Lachin (1993). The resulting CARA procedure sacrifices a
small amount of expected patient benefit in order to introduce
randomization. Our procedure differs from existing CARA
procedures by optimizing patient benefit in an unconstrained
fashion, rather than with a constraint to preserve power (e.g.,
Rosenberger, Vidyashankar, and Agarwal, 2001).
The bandit literature has very few relevant papers fol-
lowing the lines of Gittins’ work. Woodroofe (1979) studied
the optimal policy structure of a simplified special case of a
one-armed bandit problem with a covariate. Clayton (1989)
concludes that the existence of the index function depends on
the functional form of the assumed relation between outcome
and covariate (or link function), among other assumptions.
Yet, for the usual logit function, the existence of the index
is only conjectured under certain constrains on the parame-
ter space. More recently, there has been work on randomized
bandits with covariates by Yang and Zhu (2002). The authors
introduce a myopic randomized solution that is asymptoti-
cally consistent. We take a different approach, concentrating
on the introduction of covariates and randomization to the
Gittins index, by taking into account future sequences of
allocations and covariate values under the Gittins rule. Our
simple, heuristic approach thereby aims to achieve a near-
optimal mean total rewards criterion in a computationally
feasible way.
In Section 2, we introduce the modified Gittins’ rule and
demonstrate its application in a clinical trial setting with a
binary outcome and a binary covariate. We introduce our
probabilistic implementation of the modified Gittins index,
which we call the covariate-adjusted response-adaptive for-
ward looking Gittins index (CARA FLGI), in Section 3. In
Section 4, we compare our approach to alternative procedures
by performing simulations, including scenarios in the con-
text of a recently published trial (Schortgen et al., 2012). We
briefly discuss extensions to multiple polychotomous covari-
ates in Section 5. We draw conclusions in Section 6.
2. The Gittins Rule for a Model with Covariate
Information
Consider a clinical trial to test the effectiveness of T exper-
imental treatments against a control treatment on a fixed
sample of N patients. Assume T and N are fixed and
known. Before a patient n (n = 1, . . . , N) is allocated to treat-
ment t (t = 0, . . . , T ), where t = 0 denotes the control, a
binary characteristic or covariate Zn is observed for patient
n. Immediately after making a treatment decision, that is,
patient n receives treatment t, a binary outcome variable
(sucess/failure) Yt,n is observed with Pr(Yt,n = 1) = pt , the true
unknown response probability for treatment t. Assume that
Yt,n=1 if the treatment is successful and 0 otherwise. Patients
enter the trial one-by-one and the outcome for patient n is
observed before patient n + 1 appears.
Let Zn ∼ Bernoulli(q) for all n = 1, . . . , N, where Zn =
0, 1, respectively, indicates patient n is covariate negative
or covariate positive. Let Yt,n ∼ Bernoulli (pt(zn)) for all n =
1, . . . , N. For example, we can assume that for all n: pt(zn) =
Expit (αt + βtzn) for t = 0, . . . , T with αt and βt being unknown
parameters and where we have defined
Expit(u) = exp(u)
1 + exp(u) , Logit(u) = log
(
u
1 − u
)
.
We will further assume that the probability of the covariate
taking value 1, that is, q, is known. The goal is to find a patient
allocation procedure that, taking into account the covariate
and outcome observations available at each time, maximizes
the expected total number of successes after the N patients
have been treated. The resulting optimization problem will
no longer admit a Gittins index solution as each arm’s state
variable includes the covariate data, which continues to evolve
regardless of whether a treatment is allocated or not, making
the bandit formulation restless.
In order to define a Gittins index heuristic solution for this
problem with covariates, we will reformulate it as follows. We
will consider that for every treatment–covariate combination
there exists a independent arm, which will be indexed by its
covariate value and treatment arm label, that is, zt. For exam-
ple, the arm 00 is the arm corresponding to covariate value 0
and the control treatment. Therefore, there will be 2 (T + 1)
arms in this reformulated version of the classic multi-armed
bandit problem, each of which has a success rate pzt .
Let each parameter pzt be assigned a Beta(szt,0,fzt,0) prior
density at the start of the trial, where szt,0 and fzt,0 denote
prior beliefs about the relative chances of success and fail-
ure of arm zt, respectively. Given the conjugacy of the prior
and Bernoulli distributed outcome, these priors are converted
into beta posteriors for pzt via Bayes theorem as patients enter
the trial, are assigned to a treatment arm given their observed
covariate zn and subsequently experience a success or a fail-
ure. Let Xzt,n = (szt,0 + Szt,n, fzt,0 + Fzt,n) be the 2 state-vector
of available information on arm zt before treating patient n,
where the random vector (Szt,n, Fzt,n) represents the number of
successful and unsuccessful outcomes for arm zt up to patient
n. The posterior for pzt after having treated patient n and
observing szt,n successes and fzt,n failures, is: f (pzt |xzt,n) ∼
Beta(szt,0 + szt,n,fzt,0 + fzt,n) with its posterior mean being
E[pzt |xzt,n] = szt,n+szt,0szt,n+fzt,n+szt,0+fzt,0 . Finally, let azt,n be the binary
indicator variable denoting whether patient n + 1 is assigned
to arm zt or not. The multi-armed bandit optimization prob-
lem is to find an allocation rule π such that:
V ∗D(x˜0) = max
π∈
Eπ
[(
N−1∑
n=0
2(T+1)∑
t′=1
dnE[pt′ |xt′,n]at′,n
)∣∣∣x˜0,
]
. (1)
where t′ = {1, 2, . . . , T, T + 1, T + 2, . . . 2(T + 1)} stand for
00, 01, . . . , 0T , 10, 11, . . . , 1T , respectively, x˜0 = (xt′,0)2(T+1)t′=1 is
the initial joint state with all the prior parameters, Eπ[·]
denotes expectation under allocation rule π, and d is a
discount factor (i.e., 0 ≤ d < 1) introduced for reasons of
tractability, so that a trial of infinite size (N = ∞) can
be assumed. Thus, V ∗D(x˜0) is the optimal expected total
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discounted value function conditional x˜0 over , the family
of admissible allocation rules, which for this particular refor-
mulated model are those for which for all zn = 0 it holds that∑T+1
t′=1 at′,n = 1 and
∑2(T+1)
t′=T+2 at′,n = 0 while for all zn = 1 it holds
that
∑T+1
t′=1 at′,n = 0 and
∑2(T+1)
t′=T+2 at′,n = 1 (in words, those rules
that allocate an arm zt that is available for covariate value zn).
Put simply, (1) is the maximum average (discounted) number
of patients responses attainable given the initial information
on the available treatments and covariates before the start of
the trial.
The solution to (1) could in principle be found via dynamic
programming, using a backward induction algorithm. How-
ever, this becomes computationally infeasible for relatively
small values of N and 2(T + 1) and is further extremely diffi-
cult to implement in practice. A computationally tractable
solution to (1) when considered for N = ∞ based on the
indices proposed by Gittins and Jones (1979) would be to allo-
cate patient n with covariate zn to the arm that is available
for covariate zn with the highest Gittins index at time n − 1.
For arm zt at time n, and stopping time τ, this is denoted
G(xzt,n) where:
G(xzt,n) = sup
τ≥1
E
[(
τ−1∑
i=0
E[pzt |xzt,n+i]di
)
|xzt,n
]
E
[(
τ−1∑
i=0
di
)
|xzt,n
] . (2)
Here (2) represents the ratio between the total expected dis-
counted number of successes observed after allocating arm zt
from patient 1 up to τ given the initial information on arm zt
and the total expected discounted number of patients treated
with arm zt from patient 1 to τ given the initial information
on arm zt. We will refer to this solution as the CARA Git-
tins index rule (CARA GI). Notice that the index defined
by (2) depends only on the current information state of arm
zt. These Gittins indices can be calculated by solving the
problem of allocating patients optimally between treatment
zt and a known treatment which yields a constant reward.
For a detailed explanation of how the Gittins index rule is
deployed and a table with values see Tables 4 and 5 of Web
Appendix A in Villar et al. (2015).
3. The Covariate-Adjusted Response-Adaptive
Forward-Looking Gittins Index Rule
Following the approach introduced in Villar et al. (2015), we
will assume that instead of enrolling the N patients one-by-
one, patients are enrolled in groups of size b over J stages,
so that J × b = N. We wish to specify a CARA rule based on
the CARA Gittins index rule that sequentially randomizes
the next b patients among the T + 1 treatments at stage j
(j=1,. . . ,J) given the data up to block j − 1 and each of
the patients observed covariate value zn. This translates to
determining πzt,j, where: πzt,j = the probability of allocation
for patients to treatment zt at stage j (j = 1,. . . ,J), which is
common to all patients with covariate value z in block j, when
using the CARA Gittins index rule as defined in Section 2
and given data observed up to the stage j − 1 (and thus
patient (j − 1) × b), denoted by x˜(j−1)b. Note that x˜(j−1)b can
be written as a 2(T + 1) × 2 matrix in which row t′ represents
the parameters of arm t′’s current posterior distribution up
to patient (j − 1)b. This marginal probability is obtained
via the procedure next explained. Let b¯Z=1 represent the
expected number of patients with covariate positive value in a
block of size b, that is, b¯Z=1 = b × q and let aGIzt,n be the binary
variable representing if arm zt is allocated to patient n under
the CARA Gittins index rule (aGIzt,n = 1) or not (aGIzt,n = 0).
The formula below represents the probability of allocating
each combination arm zt in a block of size b¯Z=z given that
the first patient in the block has an observed covariate value
of Zn = z and when using the Gittins index rule:
πzt,j(Zn = z) = 1
b¯Z=z
jb∑
n=(j−1)b+1
[ ∑
x˜n−1∈n−1
Pr(aGIzt,n =1|X˜n−1 = x˜n−1)
Pr(X˜n−1 = x˜n−1|X˜(j−1)b = x˜(j−1)b)
]
(3)
Here n−1 represents the set of all possible values for X˜n−1
given initial data x˜(j−1)b for every future patient n in (j −
1)b + 1, . . . , jb under the CARA Gittins index rule described
in Section 2 (summarized by aGIzt,n). Each term of the sum-
mation within the square brackets of (3) represents the joint
probability of allocating a future patient n with covariate z in
block j to treatment t and the current information state at
patient n − 1, given the data at the beginning of block j − 1
and the probability of a patient being covariate positive q.
In order to compute the CARA FLGI allocation probabil-
ities for block j and arm zt (which do not depend on the
covariate value of the first patient in the block), we average
the probabilities calculated in (3) as follows:
πzt,j =
∑
Zn={0,1}
πzt,j(Zn = z)Pr(Zn = z). (4)
3.1. Worked Example
To illustrate how these probabilities are computed, imple-
mented and their computational cost, we present the simplest
case of a trial testing a control treatment (t=0) against an
experimental treatment (t=1) with a block of size 2 (i.e.,
b = 2 and 2(T + 1) = 4) and a binary covariate Z = {0, 1}.
Suppose further that in the first block of the trial, hav-
ing started with Beta(1,1) priors for all the t′ = 4 arms, the
resulting allocation was: one covariate negative patient to
control (i.e., arm t00)—one success—and a covariate posi-
tive patient to experimental t11—another success—and no
patients allocated to the remaining arms (i.e., t01, t10). Hence,
for the second block the priors for each combination arm are
x˜2 = [(2, 1); (1, 1); (1, 1); (2; 1)].
Figure 1 shows, via a probability tree, how the CARA FLGI
probabilities for block 2 given the data in block 1 are com-
puted for the first patient in the block being covariate negative
value. Given that the control treatment has the maximum
Gittins index, the allocation for the first patient of the second
block who has a covariate negative value (i.e., patient 3 with
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Figure 1. The CARA FLGI rule and a probability
tree of all trial histories using the Gittins index rule
when K = 2, b = 2, Z = {0, 1} w.p {(1 − q), q}, and x˜2 =
[(2, 1); (1, 1); (1, 1); (2, 1)]. Bold text indicates the allocated
combination arm under the Gittins index rule {aGIzk,t}. Gittins
index values used correspond to d = 0.99. Gittins indices that
have been crossed out indicate arms that are not available for
a patient given her covariate value.
z3 = 0) is deterministic. It follows that Pr(aGI00,3 = 1|x˜2) = 1
and Pr(aGI01,3 = 1|x˜2) = 0.
When the second patient of the second block is to be
allocated (i.e., patient 4), given that we have allocated the
control treatment to the first patient, two possible outcomes
can occur. If a success occurs, which happens with probabil-
ity 2/3, then the control treatment is allocated again if the
next patient is covariate negative. If a failure occurs and the
next patient is covariate negative then the experimental treat-
ment is allocated. If the next patient is covariate positive, the
experimental treatment is allocated regardless of the previous
outcome. Hence, Pr(aGI00,4 = 1|x˜2) =
∑
x˜3∈3 Pr(a
GI
00,4 = 1|X˜3 =
x˜3)Pr(X˜3 = x˜3|x˜2) reduces to 2/3(1 − q), while Pr(aGI01,4 =
1|x˜2) =
∑
x˜3∈3 Pr(a
GI
01,4 = 1|X˜3 = x˜3)Pr(X˜3 = x˜3|x˜2) reduces
to 1/3(1 − q). Using (3), we can obtain π00,2(Z3 = 0) =
(1 + 2/3(1 − q))/1 and π01,2(Z3 = 0) = (0 + 1/3(1 − q))/1. A
similar reasoning for the first patient in the block being covari-
ate positive, given the data in block 1, yields π00,2(Z3 =
1) = (0 + 1/3(1 − q) + 2/3(1 − q))/1 = (1 − q) and π01,2(Z3 =
1) = (0 + 0)/1 = 0. Using (4), we can compute that: π00,2 =
(1 + 2/3(1 − q)) ∗ (1 − q) + (1 − q) ∗ q and π01,2 = (1/3(1 −
q)) ∗ (1 − q) + 0 ∗ q. If q = 1/2, then π00,2 = 11/12 and
π01,2 = 1/12. Analogous calculations result in π10,2 = 1/12
and π11,2 = 11/12.
From this example, it is clear that the computational cost
of computing the πzt,j’s, which depend on the joint state for
the 2(T + 1)-arms, that is, x˜n (instead of the 1 arm state
xn), will grow exponentially as b and T increase. Hence,
we use a Monte-Carlo algorithm for this purpose. It fol-
lows that for Zn = z if we plug (3) into (4) the πzt,j’s add
up to 1.
4. Simulation Study
In the following, we assume that responses for treatment t
satisfy the following logistic model: Logit (pt(zn)) = αt + βtzn,
where αt is treatment’s t effect, and βt is the effect due to
the binary covariate Z in treatment group t. The parame-
ter of interest is the covariate-adjusted treatment difference,
defined as αt − α0 for t = 1, . . . , T . The covariate Z is assumed
to be independently distributed as a Bernoulli(pz), where
pz is known before the start of the trial. Notice that the
model allows for treatment–covariate interaction, since the
covariates effects coefficients βt ’s are allowed to vary across
treatments.
We now evaluate the properties of the proposed CARA
procedures by simulation, focusing on operating characteris-
tics that include measures of validity, efficiency, balance and
ethics. The validity of the procedures is measured by the aver-
age significance level or type I error rate α of the test under
the null hypothesis. To assess the chance of a type I error
being made under the global null in a multi-arm setting, we
report the family-wise error rate α¯. This is the probability
of rejecting at least one true null hypothesis. The Bonferroni
method is used to account for multiple testing and ensure that
α¯ ≤ α, that is, all hypothesis whose p-values are less than α
K
are rejected (with α = 0.05). The efficiency of procedures is
measured by the average statistical power (1 − β) of the test
used. To assess power in a multi-arm setting, we calculate
the probability of rejecting the null for the truly best treat-
ment under each assumed scenario. The balance measures
of procedures considered are the average allocation propor-
tion per treatment Nt(N)/N for t = 0, . . . , T . For a measure
of (im)balance and ethics, we consider the average allocation
proportion of patients within Z category assigned to the best
treatment for that category N(zt)∗(N)/N. The ethical perfor-
mance of the procedures is assessed by the expected total
number of treatment failures (ENF) and the average propor-
tion of patients assigned to the best treatment p∗, defined
as pz × N(1t)∗(N)/N + (1 − pz) × N(0t)∗(N)/N. Finally, for a
combined measure (CM) of the power-ethics trade-off, we
report the percentage of trial realizations in which: (1) 85% or
more patients with biomarker 0 received the best arm under
H1 and (2) resulted in a statistically significant treatment
difference.
We compare both the deterministic and randomized
GI-based CARA procedures to the following established
CARA allocation procedures for the logistic regression
model:
(1) Equal randomization (ER): patients within a covariate
group are allocated between the T experimental arms
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and the control arm with a fixed and equal probability
of 1
(T+1) .
(2) CARA 1: Rosenberger, Vidyashankar, and Agarwal
(2001) propose the allocation target:
ρ10(z) =
p0(z)/q0(z)
p0(z)/q0(z) + p1(z)/q1(z) , (5)
where pt(z) = Expit(αt + βtz) and qt(z) = 1 − pt(z).
(3) CARA 2: the allocation ratio proposed in Rosenberger
et al. (2001):
ρ20(z) =
√
p0(z)√
p0(z) +
√
p1(z)
, (6)
(4) CARA 3: covariate-adjusted version of Neyman alloca-
tion:
ρ30(z) =
√
p1(z)q1(z)√
p0(z)q0(z) +
√
p1(z)q1(z)
, (7)
(5) CARA 4: covariate-adjusted version of optimal alloca-
tion:
ρ40(z) =
√
p1(z)q1(z)√
p0(z)q0(z) +
√
p1(z)q1(z)
, (8)
(6) Thompson CARA Sampling (TS) (Thompson, 1933):
patients within a covariate group are allocated between
the experimental arms and the control arm with a prob-
ability proportional to the posterior probability that
pzt is the largest response rate given the observed data.
Specifically, we defined πTSzt,j =
Pr(maxi pi=pzt |x˜(j−1)b)c∑
i|Z=z Pr(maxi pi=pzt |x˜(j−1)b)
c
with c = J
2T
.
(7) Stratified permuted block design (SPBD): the stra-
tum of the current patient is determined based on the
patient’s observed covariate value. Within that stratum
allocations are made using a permuted block of size m
(m is reported for every simulation).
Note that in choosing which rules to compare our procedure
against, we wanted to include all related methods and those
that are used in practice. However, it is important to high-
light that all of these methods are essentially different in that
they are designed to achieve different goals (power, balance,
or ethics). In all simulations, we use a uniform Beta(1,1) prior
for each arm and we compute the allocation probabilities for
CARA FLGI using a Monte-Carlo approximation based on
102 replications. For the CARA procedures in (2)–(5), the
first 50 patients are randomized following an ER procedure.
After those 50 allocations, the maximum likelihood estima-
tors of αt and βt are computed, and the associated estimate
of the treatments success rates pt(z) is sequentially used for
computing the allocation probabilities.
4.1. The Sepsicool Trial
The Sepsicool trial, as reported by Schortgen et al. (2012),
evaluated the effect of fever control by external cooling
on vasopressor requirements in septic shock. Septic shock,
defined as sepsis with cardiovascular failure requiring vaso-
pressor infusion, has a high mortality rate (40–60%). Current
recommendations focus on the first few hours of sepsis man-
agement but the criteria for vasopressor selection remains
debated. The original trial allocated 200 patients between the
two arms with a fixed and equal randomization probability
of 1/2. The primary endpoint (number of patients with 50%
decrease in the baseline vasopressor dose) was available 48
hours after randomization. The secondary endpoints included
all-cause mortality on day 14. At the end of the trial, the dif-
ference in the primary endpoint between treatments was not
found to be statistically significant. However, day 14 mortal-
ity rate was significantly lower in the cooling group (19% vs.
34%). Furthermore, post hoc analyses adjusting on the base-
line vasopressor dose differed significantly between treatment
groups, indicating that the significant effect of cooling was
more pronounced in patients having the lowest baseline vaso-
pressor doses (i.e., those that had a lower illness severity).
The reported odds-ratio (OR) before and after adjustment
for covariates with baseline imbalances (a combination of dose
and illness severity), respectively, were 0.44 and 0.36.
We show the impact of redesigning the Sepsicool study
to account for such covariate data using the CARA GI
and CARA FLGI and the alternative CARA patient allo-
cation rules. We dichotomize patients by dose-severity into
two groups: high or moderate versus low illness severity-
dose combination. We let covariate z take the value 0 when
a patient is from the high or moderate severity group. We
report the results for two scenarios of parameter values: αt =
0.6482, βt = 0 for t = 0, 1 (Scenario 1) and α0 = 0.6482, β0 =
0, α1 = 1.6702, β1 = −0.3793 (Scenario 2). Scenario (1) repre-
sents the null hypothesis where there is no treatment effect
nor treatment–covariate interaction while Scenario 2 repre-
sents a possible parameter realization compatible with the
values reported after the Scepsicool trial. The values for
Scenario 2 are arbitrary but chosen so as to be consistent
with the overall and adjusted ORs reported by the trial
in Schortgen et al. (2012), as response data per covariate
group is not publicly available, and neither is the informa-
tion on the covariate distribution. Therefore we assume that
patients are equally distributed between these two groups
(i.e., pz = 0.5).
The sample size was chosen to be of N = 450 so that ER
achieves at least 90% in Scenario 1. For the CARA FLGI, we
fix the block size to b = 10, 30, 45, 50 patients and the number
of interim analysis to J = 45, 15, 10, 9. For SPBD the block
size was set to m = 10.
Hypothesis testing was performed using a normal cut-off
value (when appropriate) and using an adjusted version of
Fisher’s exact test for comparing two binomial distributions.
Fisher’s test has an actual rejection rate far below the nom-
inal significance level. To make the designs comparable and
suitable for response-adaptive bandit rules we chose its cut-
off value from simulations so as to achieve the nominal type
I error rate (Villar et al., 2015). Under the null, p∗ is defined
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as the mean proportion of patients assigned to the control
group, whereas under the alternative, p∗ is computed as the
mean proportion assigned to arm 1.
4.2. Results
Table 1 displays the results from 5000 replications of the
trial. As expected, under Scenario 1 (bottom of Table 1)
all the designs are equal in terms of ENF and p∗ (ENF is
T × 0.3434 = 154.53). All rules allocate on average the same
proportion of patients with a given covariate value to each
treatment (close to 0.50). The CARA Gittins index designs
have a variability in the allocation probabilities between 5 and
10 times larger than the other CARA designs.
The most interesting differences among these designs occur
under Scenario 2 (top of the table). We find that the CARA GI
and CARA FLGI procedures decrease the expected number of
deaths dramatically compared to ER (approximately 30 less
deaths on average).
The efficiency of procedures under Scenario 2 was mea-
sured by the average power of the test to reject the null
hypothesis of no covariate-adjusted treatment difference (i.e.,
α1 − α0 = 0). Of particular interest is the potential conflicts
among balance, efficiency, and ethics goals that result from
the different methods. All CARA designs are more variable
than the rules that achieve balance. Some of them achieve
slightly higher levels of power and similar values of ENF than
ER (CARA 3) while others offer a slightly reduced power
accompanied by a reduction in their ENF (CARA 1) when
compared to ER. As expected, the designs that have the
smallest ENF (and therefore the highest performance in terms
of the ethical goal) and p∗ are the Gittins index-based ones.
However, these rules also have the largest variability of allo-
cation probabilities and the lowest power levels. Naturally,
these designs also have a much larger variability and lower
power than CARA procedures designed to optimize patient
benefit while simultaneously achieving a power constraint (as
CARA 4 does). However, this larger variability is associated
with highly skewed patient allocations only under H1.
These results suggest that the conflict between power and
balance can be less acute than that between balance/power
and ethics, but just as in the two-armed case with no covari-
ates, a conflict between both of these objectives and the
ethical one will always be present. In other words, in a two-
armed context any modification of the CARA GI rules aimed
at increasing its statistical power result in a worsening of its
performance in terms of patient benefit. This power-ethics
trade-off is particularly acute when the disease is fatal and
rare. The CM measure suggests that only GI-based designs
and TS have some trial realizations that meet this dual power-
ethics criterion. Next, we explore the multi-armed case, the
main motivation for this article.
4.3. Multi-Armed Trials: The Controlled CARA FLGI
We next create a simulation scenario to evaluate the
effect of increasing the number of treatments on the
ethics-power relation of the proposed CARA GI allocation
methods. We consider a trial of size N = 300 with three
arms (i.e., K = 2). The assumed parameters per arm are:
(αt, βt) = {(−0.052,−0.473); (−1.252, 1.152); (−0.652, 1.552)}
which corresponds to the following success rates vectors
(0.2224; 0.3425; 0.4870) (for covariate negative patients) and
(0.4750; 0.7109; 0.3717) (for covariate positive patients).
Therefore, in this scenario there exists a treatment–covariate
interaction: the best arm for covariate negative patients is
experimental arm 2 while for covariate positive patients is
experimental arm 1. As in the previous section, we assume
that patients are equally distributed between these two
groups (i.e., q = 0.5).
We compare the CARA FLGI procedures to ER, SPBD,
and TS. Additionally, we heuristically extend CARA 1 and
CARA 2 to, respectively, use the following allocation targets:
ρ1t (z) =
pt(z)/qt(z)∑K
t=0 pt(z)/qt(z)
, ρ2t (z) =
√
pt(z)∑K
t=0
√
pt(z)
. (9)
Notice that these heuristics are no longer expected to opti-
mal, as shown in Tymofyeyev et al. (2007) for multi-arm case
with no covariate variables the extension is far from trivial.
Procedures CARA 3 and CARA 4 are not simply extended
into a heuristics rule for a multi-armed context and therefore
not included in this section. In addition to the CARA FLGI
rule defined by (4), we shall consider a controlled group allo-
cation rule (CARA CFLGI) which, similarly to the CFLGI
introduced in Villar et al. (2015), protects the allocation to
the control treatment so that it remains fixed at 1
(K+1) per
covariate group during the trial.
Table 2 reports the results of 5000 replications of this trial
under the scenario above described and for each of the CARA
designs considered. The operating characteristics reported
are the same as before with the exception of the efficiency
and ethics measures. The efficiency is measured in this case
by the average marginal statistical power of the test used
to detect that arm 2 is best for covariate negative patients
(1 − β0) or to detect that arm 1 is best for covariate pos-
itive patients (1 − β1). The ethical performance is measured
by the expected number of successes (ENS) rather than ENF.
CM counts realizations that: (1) assigned 75% or more covari-
ate 0 patients to their best arm and (2) had a statistically
significant result.
As expected, the CARA GI-based rules perform extremely
well in terms of patient benefit (with CARA GI achieving on
average 38 more successes than a ER design) and extremely
poorly in terms of marginal power and the variability of
the resulting allocations. On the other hand, CARA 1 and
CARA 2 have lower and similar levels of variability yet they
result in different performances in terms of patient benefit and
marginal power. The controlled class of CARA FLGI alloca-
tion rules results in higher values of marginal power than ER
for both patient subgroups while offering and advantage in
terms of patient benefit of 13–16 more successes on average
depending of the block size selected. Notice that these con-
trolled procedures achieve variability levels similar to CARA
1 and CARA 2.
5. Extensions: Polychotomous Covariates and
Multiple Covariates
Let Zn ∼ Multinomial(q0, q1, . . . , qM) for Zn ∈ {0, 1, . . . ,M}
where M is a finite number, that is, P(Zn = i) = qi for i =
0, 1, . . . ,M. A CARA GI heuristic solution as in Section 2
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Table 1
Redesigning the Sepsicool trial. Results from 5000 replications for different CARA procedures, N = 450
Alternative
Procedure b (1 − β) N0(N)/N (s.d) N0t∗(N)/N (s.d) N1t∗(N)/N (s.d) ENF (s.d) p∗(s.d) CM
ER 1 0.91 0.500 (0.02) 0.500 (0.03) 0.500 (0.04) 119.22 (9.24) 0.500 (0.02) 0.0
SPBD 10 0.90 0.500 (0.02) 0.500 (0.02) 0.500 (0.02) 119.14 (9.39) 0.500 (0.02) 0.0
CARA 1 10 0.88 0.330 (0.06) 0.697 (0.09) 0.626 (0.09) 106.94 (10.23) 0.662 (0.07) 1.5
CARA 2 10 0.91 0.476 (0.03) 0.528 (0.04) 0.520 (0.04) 117.54 (9.36) 0.524 (0.03) 0.0
CARA 3 10 0.91 0.453 (0.03) 0.560 (0.04) 0.532 (0.04) 115.81 (9.50) 0.547 (0.03) 0.0
CARA 4 10 0.89 0.391 (0.04) 0.638 (0.06) 0.578 (0.06) 111.02 (9.91) 0.609 (0.04) 0.0
TS 10 0.89 0.301 (0.06) 0.737 (0.08) 0.660 (0.09) 104.68 (9.42) 0.699 (0.06) 6.2
CARA FLGI 50 0.44 0.142 (0.09) 0.810 (0.19) 0.904 (0.07) 92.30 (9.53) 0.858 (0.09) 38.0
CARA FLGI 45 0.38 0.123 (0.10) 0.896 (0.15) 0.856 (0.16) 91.90 (10.71) 0.877 (0.10) 28.0
CARA FLGI 30 0.42 0.108 (0.09) 0.851 (0.19) 0.931 (0.05) 90.30 (10.13) 0.892 (0.09) 30.0
CARA FLGI 10 0.20 0.133 (0.17) 0.902 (0.23) 0.830 (0.27) 90.94 (13.96) 0.867 (0.17) 18.0
CARA GI 1 0.18 0.102 (0.14) 0.930 (0.16) 0.864 (0.25) 91.54 (12.84) 0.898 (0.14) 14.0
Null
Procedure b α N0(N)/N (s.d) N0t∗(N)/N (s.d) N1t∗(N)/N (s.d) ENF (s.d) p
∗(s.d) CM
ER 1 0.05 0.500 (0.02) 0.500 (0.03) 0.500 (0.03) 154.33 (9.95) 0.500 (0.02) 0.0
SPBD 10 0.05 0.500 (0.02) 0.501 (0.02) 0.500 (0.02) 154.58 (9.95) 0.500 (0.02) 0.0
CARA 1 10 0.05 0.500 (0.06) 0.500 (0.09) 0.500 (0.09) 154.44 (10.22) 0.500 (0.06) 0.0
CARA 2 10 0.05 0.500 (0.03) 0.500 (0.04) 0.500 (0.04) 154.28 (10.03) 0.500 (0.03) 0.0
CARA 3 10 0.05 0.500 (0.02) 0.500 (0.03) 0.499 (0.04) 154.53 (10.13) 0.499 (0.03) 0.0
CARA 4 10 0.05 0.500 (0.04) 0.500 (0.05) 0.499 (0.05) 154.41 (10.05) 0.499 (0.04) 0.0
TS 10 0.06 0.501 (0.07) 0.501 (0.10) 0.501 (0.10) 154.61 (10.14) 0.501 (0.07) 0.0
CARA FLGI 50 0.06 0.555 (0.28) 0.523 (0.24) 0.490 (0.33) 155.76 (11.23) 0.522 (0.24) 4.0
CARA FLGI 45 0.04 0.533 (0.23) 0.522 (0.34) 0.544 (0.29) 155.42 (10.22) 0.533 (0.23) 4.0
CARA FLGI 30 0.04 0.481 (0.35) 0.535 (0.27) 0.586 (0.38) 154.22 (10.10) 0.535 (0.27) 2.0
CARA FLGI 10 0.04 0.467 (0.31) 0.463 (0.42) 0.472 (0.39) 152.52 (9.44) 0.467 (0.31) 4.0
CARA GI 1 0.06 0.512 (0.29) 0.555 (0.40) 0.467 (0.42) 154.78 (10.28) 0.512 (0.29) 2.0
for this case can be defined by considering that for every
treatment–covariate combination there exists a independent
arm, indexed by its covariate value and treatment arm label,
that is, zt. Therefore, there will be (M + 1)(T + 1) arms in this
reformulated the classic multi-armed bandit problem, each of
which has a success rate pzt .
If there are C possible covariate variables and Zn is a
C × 1 vector, where C is a finite number. Suppose each indi-
vidual covariate c can take Mc different values where Mc is
finite and specific for each covariate. A CARA GI heuris-
tic solution as in Section 2 for this case can be defined by
redefining all the covariates into a single covariate having
Table 2
Results from 5000 replications for different CARA procedures, N = 300: arm 1 is best for covariate positive patients and arm
2 is best for covariate negative patients
Procedure b (1 − β0) (1 − β1) N0(N)/N (s.d) N0t∗(N)/N (s.d) N1t∗(N)/N (s.d) ENS (s.d) p∗(s.d) CM
ER 1 0.77 0.69 0.334 (0.03) 0.334 (0.04) 0.333 (0.04) 132.01 (8.44) 0.334 (0.03) 0.0
SPBD 12 0.75 0.71 0.334 (0.02) 0.333 (0.03) 0.333 (0.03) 131.91 (8.36) 0.333 (0.02) 0.0
CARA 1 10 0.64 0.74 0.221 (0.06) 0.507 (0.11) 0.566 (0.09) 149.15 (9.64) 0.538 (0.07) 0.2
CARA 2 10 0.67 0.73 0.296 (0.05) 0.398 (0.07) 0.388 (0.05) 137.39 (8.62) 0.393 (0.04) 0.0
TS 10 0.71 0.75 0.224 (0.05) 0.485 (0.09) 0.592 (0.09) 149.28 (9.49) 0.542 (0.06) 1.0
CARA CFLGI 50 0.78 0.74 0.340 (0.02) 0.513 (0.11) 0.597 (0.05) 149.98 (8.27) 0.558 (0.06) 0.0
CARA CFLGI 10 0.82 0.88 0.331 (0.03) 0.516 (0.13) 0.637 (0.05) 151.44 (9.43) 0.580 (0.06) 0.0
CARA FLGI 50 0.32 0.02 0.100 (0.04) 0.653 (0.20) 0.843 (0.06) 167.06 (10.72) 0.754 (0.09) 5.0
CARA FLGI 30 0.30 0.04 0.085 (0.05) 0.688 (0.25) 0.878 (0.08) 167.86 (9.46) 0.789 (0.12) 8.0
CARA FLGI 20 0.16 0.04 0.100 (0.07) 0.711 (0.23) 0.866 (0.09) 168.40 (9.51) 0.793 (0.11) 4.0
CARA FLGI 10 0.24 0.02 0.068 (0.05) 0.776 (0.18) 0.885 (0.13) 171.72 (11.25) 0.834 (0.11) 4.0
CARA GI 1 0.08 0.04 0.054 (0.04) 0.704 (0.29) 0.937 (0.06) 171.42 (11.80) 0.828 (0.14) 2.0
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S = M1 × M2 × . . . × MC stratification levels. Again, we con-
sider that for every treatment–covariate level there exists a
independent arm, indexed by its covariate value and treat-
ment arm label. Therefore, there are S(T + 1) arms in this
reformulated multi-armed bandit problem.
In both cases, the GI CARA procedure assigns patient n
with covariate zn to the arm available given its covariate pro-
file with the highest Gittins index after observing patient’s
n − 1 outcome. The computationally feasibility of the Gittins
index rule ensures the tractability of the CARA GI procedure
regardless of the size of M or Mc.
6. Discussion
Over the past few years, “precision medicine” (the tailor-
ing of medical treatment to the individual characteristics of
each patient) has shown promise through the approval of new
cancer therapies for patients with specific genetic mutations.
The challenge to precision medicine is that many promising
new treatments have relatively few patients to test them, and
even fewer patients when a treatment works only within a
biomarker subgroup. Novel methodology for trial design that
is able to identify superior treatments more quickly, mainly
treatments that work better within subgroups, is an essential
requirement to make precision medicine possible.
Non-myopic block adaptive randomization procedures
based on the Gittins index have recently been proposed to
offer patient benefit within a trial by more quickly identify-
ing a superior arm if it exists. In this article, we introduce a
bandit-based CARA design which can incorporate biomaker
information that is potentially predictive of patient outcome.
Through simulations, we illustrate how the proposed CARA
FLGI procedure enables adaptively block-randomized clini-
cal trials that are statistically conservative when no superior
treatment exists and highly ethical in terms of patient ben-
efit. Such a procedure satisfies the dual goals of differential
treatment responses while satisfying an ethical imperative.
A limitation of the resulting CARA design is its high vari-
ability leading to a corresponding power loss. Although in the
two-armed context this reduced power is unavoidable without
a corresponding sacrifice in patient benefit, in a multi-armed
context, these CARA designs offer important simultaneous
patient benefit and power gains over a traditional design. A
caveat to these results is that they require a temporal homo-
geneity of the blocks of patients recruited, as a time trend
could cause an inflation of the type I error.
The derivation of the allocation probabilities with the pro-
posed CARA design is considerably more complex than that
of the existing alternative procedures. However, its practi-
cal implementation is as feasible as that of other methods,
given its low computational cost. Moreover, the patient bene-
fit advantages of the proposed design grow with the number of
arms under study. In cases in which the endpoint is survival
and there are very few patients with the condition, designs
that prioritize patient benefit and allocate more patients to
the best treatment according to their covariate profile, as the
proposed CARA FLGI does, should be carefully considered
as part of trial design.
We have demonstrated that the CARA FLGI can have
favorable effects in a redesigned clinical trial, with minimal
computational difficulties. The careful biostatistician can con-
sider the relative benefits of such a design; if power is the
most important component, then the methods of Zhang et al.
(2007) present one alternative CARA method.
7. Supplementary Materials
Example code and instructions for running it are available
with this article as a web supplement at the Biometrics web-
site on Wiley Online Library.
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